Ali KOCATAŞ, Mehmet Abdussamet BOZKURT, Osman KÖNEŞ, Süleyman BÜYÜKAŞIK, Halil ALIŞ

Familyal Adenomatöz Polipozisli Bir Hastada Nöroendokrin Tümör ve Adenokarsinom Birlikteliği

Familyal adenomatöz polipozis (FAP) sendromu kolonda nadir görülen genetik geçişli bir sendromdur. Eğer tedavi edilmezse yaşam boyu kanserleşme oranı %100dür. FAPlı hastalarda adenokanserler de görülebilir. Biz kliniğimizde mekanik barsak obstrüksiyon nedeniyle ameliyat edilen FAPlı bir hastada adenokanser ve nöroendokrin tümör birlikteliğini sunmak istedik. Hastamız literatür incelemesinde karaciğer metastazı olmadan iki ayrı tümörün birlikte görüldüğü ilk hastadır.

Co-Occurance of A Neuroendocrine Tumor and An Adenocarcinoma in A Patient with Familial Adenomatous Polyposis

Familial adenomatous polyposis (FAP) is a rare hereditary syndrome of colon. If FAP is not treated the life time risk of developing a colorectal cancer is 100%. Adenocarcinomas may also develop in FAP patients. We want to present a patient with co-ocurrance of an adeocarcinoma andneuroendocrine tumor, who had FAP syndrome and was operated in our clinic for acute mechanic intestinal obstruction. This is the first case inliterature, who was presented with co-occurance of two different tumors, without any liver metastases. a the

PDF

___

Burn J, Mathers J, Bishop DT. Genetics, inheritance and strategies for prevention in populations at high risk of colorectal cancer (CRC). Recent Results Cancer Res 2013; 191: 157-83.
Çelik S, Özenç MA, Hamaloğlu E, Karakoç D. Familyal adenomatöz polipozis ile ilişkili iki desmoid tümör olgusu ve literatürün değerlendirilmesi. Ulusal Cerrahi Dergisi 2011; 27: 235-9.
Bosman FT, Organization WH, and Cancer IAFRO (2010). WHO classification of tumours of the digestive system. Lyon: International Agency for Research on Cancer. Rev Med Suisse Romande 2000; 120: 189-90.
Modlin IM, Lye KD, Kidd M: A 5-decade analysis of 13,715 carcinoid tumors. Cancer 2003; 97: 934-59.
Yao JC, Hassan M, Phan A, et al. One hundred years after carcinoid: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008; 26: 3063-72.
Garcia-Carbonero R, Capdevila J, Crespo-Herrero G, et al. Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): results from the National Cancer Registry of Spain (RGETNE) (RGETNE). Ann Oncol 2010; 21: 1794-803.
Ploeckinger U, Kloeppel G, Wiedenmann B, Lohmann R. The German NET-registry: an audit on the diagnosis and therapy of neuroendocrine tumors. Neuroendocrinology 2009; 90: 349-63.
Grau García C, Soto Gutierrez A, Andrada Becerra E, et al. Familial adenomatous polyposis and liver metastases from a neuroendocrine tumor]. Gastroenterol Hepatol 2011; 34: 329- 32.
Krausch M, Raffel A, Anlauf M, Schott M, Lehwald N, Krieg A, et al. Secondary malignancy in patients with sporadic neuroendocrine neoplasia. Endocrine 2013; 44: 510-6.